Niche medicine paves the way for hard-tried Biotech
Several small biotech companies have found a refuge in the generally hard-tried biotech business. If companies put their efforts into niche medicine, fewer clinical trials are needed, and at the same time the European Union backs the projects financially. Now the industry wants rare diseases put on the agenda during the Danish presidency of the EU.
af LEONORA BECK
It can be difficult for smaller biotech companies to compete with the capital power and R&D levels of large pharmaceutical companies. That is why an increasing number of smaller actors in the pharmaceutical industry try their hands at drugs for rare diseases, the so-called orphan drugs.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
